Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 33

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 33
---
 Laboratory of Molecular Biology in Cambridge. Dr. Teichmann was a Beit Memorial Fellow at University College London from January 2000 to September 2001. She is a European Molecular Biology Organization (EMBO) member and a Fellow of the Academy of Medical Sciences and Royal Society, as well as a Fellow of the International Society of Computational Biology. Dr. Teichmann received a Ph.D. in Computational Genomics, as well as a B.A. and M.A. in Natural Sciences (Biochemistry), from the University of Cambridge. 
 WE BELIEVE THAT DR. TEICHMANN IS QUALIFIED TO SERVE ON OUR BOARD OF DIRECTORS BECAUSE OF HER EXTENSIVE ACADEMIC AND INDUSTRY LEADERSHIP. AND EXPERIENCE.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Sarah Teichmann      
 Age: 49              
 Director Since: 2024 |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

#### Vote Required
The election of a Class III director requires a majority of the votes cast at the 2025 Annual Meeting by the stockholders present or represented by proxy at the meeting and voting on the proposal. Under this requirement, in order for a nominee to be elected, the number of shares voted FOR the nominee must exceed the number of shares voted AGAINST with respect to such nominee. Broker non-votes and abstentions will have no effect on this proposal.

#### 10X GENOMICS, INC.292025 PROXY STATEMENT
Proposal Two

Ratification of Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025

#### 10X GENOMICS, INC.302025 PROXY STATEMENT
Fees Paid to the Independent Registered Public Accounting Firm

The following table presents fees for professional audit services and other services rendered to us by Ernst & Young LLP for our fiscal years ended December 31, 2024 and 2023.

|                       |     |           | 2024 
 ($)  |     |           | 2023 
 ($)  |
| Audit Fees(1)         |     | 2,988,954 |      |     | 2,557,125 |      |
| Audit-Related Fees(2) |     |         — |      |     |         — |      |
| Tax Fees(3)           |     |   268,